Arvinas (ARVN) Earnings Date & Reports

Key Takeaways

• Arvinas reported a third-quarter 2026 GAAP net loss of $53.9 million, or $0.82 per share, compared with a net loss of $35.1 million, or $0.48 per share, a year earlier; the per-share result still beat consensus estimates.
• Quarterly revenue fell to $0.5 million from $41.9 million a year ago, as deferred Pfizer vepdegestrant collaboration revenue and a prior-year Novartis milestone did not recur.
• Operating expenses declined sharply, with total costs at $59.6 million versus $85.7 million a year earlier, reflecting disciplined capital allocation.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $558.9 million as of September 30, 2026, with runway guided into the second half of 2028.
• Management reaffirmed multiple near-term clinical catalysts, including ARV-393 data at the December 2026 ASH conference and further readouts in 2027.
• For additional context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for a more complete view.
• You can also discover market opportunities using Trending AI Robots, which highlight AI-driven trading strategies across a range of stocks and ETFs.

Earnings Context and Why It Matters

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation through its PROTAC (proteolysis targeting chimera) platform, which uses the body's natural protein-disposal system to eliminate disease-causing proteins. Because it has no approved product revenue of its own, investors track quarterly results less for sales than for expense discipline, cash runway, and pipeline execution. This quarter mattered because the company's top line reset to royalty-only income after deferred Pfizer collaboration revenue was fully recognized in the prior quarter. The earnings update therefore served as a checkpoint on whether management is extending its financial runway while advancing multiple early-stage programs toward data readouts that could redefine the pipeline's value.

Reported Results

For the third quarter ended September 30, 2026, Arvinas reported revenue of $0.5 million, down from $41.9 million in the prior-year period. The decline reflects the absence of roughly $20.6 million in Pfizer vepdegestrant collaboration revenue and a $20.0 million Novartis development milestone recognized a year earlier. Current revenue consisted almost entirely of sales-based royalties under the Rigel Pharmaceuticals license agreement, which produced its first payment of $0.5 million.

The company posted a GAAP net loss of $53.9 million, or $0.82 per basic and diluted share, compared with a net loss of $35.1 million, or $0.48 per share, in the third quarter of 2025. While the loss widened year over year, the per-share result was better than consensus estimates. The wider net loss primarily reflected the loss of prior-year collaboration and milestone revenue and lower interest income, even as operating expenses fell.

Cost discipline was a highlight. GAAP research and development (R&D) expense declined to $46.9 million from $64.7 million, driven by a $14.2 million reduction in vepdegestrant spending. GAAP general and administrative (G&A) expense fell to $12.6 million from $21.0 million. Total operating expenses were $59.6 million versus $85.7 million a year earlier. The company ended the quarter with $558.9 million in cash and marketable securities and reiterated that its balance sheet should fund operations into the second half of 2028.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotechnology names like Arvinas, it can offer a structured way to surface actionable candidates alongside broader market trends.

Market Reaction and Investor Sentiment

Shares of Arvinas traded lower following the report, as investors weighed a wider net loss and a top line that missed consensus estimates against meaningfully reduced operating expenses and a cash runway extending into 2028. For a clinical-stage biotech, the headline revenue miss carried less weight than usual because it reflected a known structural shift in the company's revenue model rather than weakening demand. Sentiment instead centered on the pipeline: management reaffirmed plans to share data from its BCL6, polyQ-AR, and HPK1 degrader programs in the fourth quarter of 2026 and into 2027, positioning the stock for catalyst-driven trading rather than earnings-driven moves in the near term.

Forward Outlook and Key Factors to Monitor

The most immediate catalyst is ARV-393, the company's oral BCL6 degrader for lymphoma, with initial Phase 1 monotherapy dose-escalation data expected at the American Society of Hematology (ASH) annual meeting in December 2026. Investors will watch for safety, tolerability, target engagement, and early efficacy signals in patients with T-cell lymphoma, with a fuller B-cell dataset anticipated in mid-2027.

Two additional Phase 1 programs are advancing. ARV-027, a first-in-class oral androgen-receptor degrader targeting spinal-bulbar muscular atrophy (SBMA), is expected to deliver initial healthy-volunteer data and begin dosing SBMA patients in the first half of 2027. ARV-6723, an oral HPK1 degrader in immuno-oncology, began patient dosing in the third quarter, with initial data guided to the second half of 2027.

One area of uncertainty is ARV-102, the LRRK2 degrader for neurodegenerative disease. Its U.S. Investigational New Drug (IND) application remains on clinical hold, and the company now plans to prioritize a Phase 1b trial in progressive supranuclear palsy in the European Union and United Kingdom, pending regulatory authorization. Investors should monitor resolution of the U.S. hold and trial-initiation timing.

Finally, watch expense trends and cash consumption. With revenue now limited largely to royalties, Arvinas's valuation will increasingly hinge on clinical execution and its ability to extend runway through disciplined spending as it approaches multiple data inflection points across 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations